Salim Syed
Stock Analyst at Mizuho
(3.13)
# 1,164
Out of 5,239 analysts
87
Total ratings
45.83%
Success rate
2.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Initiates: Outperform | $50 | $40.91 | +22.22% | 1 | Apr 30, 2026 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $106 | $65.95 | +60.73% | 9 | Apr 28, 2026 | |
| AUTL Autolus Therapeutics | Maintains: Outperform | $12 → $10 | $1.60 | +525.00% | 1 | Mar 31, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $45 → $43 | $20.41 | +110.68% | 1 | Mar 31, 2026 | |
| NKTX Nkarta | Maintains: Outperform | $14 → $12 | $3.28 | +265.85% | 9 | Mar 31, 2026 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $41 → $45 | $42.30 | +6.38% | 2 | Mar 25, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $22 → $27 | $6.79 | +297.64% | 6 | Mar 25, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $84 → $100 | $74.81 | +33.67% | 8 | Mar 18, 2026 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $97 | $25.78 | +276.26% | 1 | Mar 10, 2026 | |
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $99.13 | +22.06% | 1 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $40 | $30.82 | +29.79% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $207 → $169 | $199.36 | -15.23% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $280 | $336.29 | -16.74% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $117 | $134.94 | -13.29% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $163 | $54.03 | +201.68% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $25 → $18 | $9.81 | +83.49% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $52.83 | +87.39% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.71 | +1,128.07% | 5 | Nov 16, 2022 |
Sutro Biopharma
Apr 30, 2026
Initiates: Outperform
Price Target: $50
Current: $40.91
Upside: +22.22%
BridgeBio Pharma
Apr 28, 2026
Reiterates: Outperform
Price Target: $106
Current: $65.95
Upside: +60.73%
Autolus Therapeutics
Mar 31, 2026
Maintains: Outperform
Price Target: $12 → $10
Current: $1.60
Upside: +525.00%
Syndax Pharmaceuticals
Mar 31, 2026
Maintains: Outperform
Price Target: $45 → $43
Current: $20.41
Upside: +110.68%
Nkarta
Mar 31, 2026
Maintains: Outperform
Price Target: $14 → $12
Current: $3.28
Upside: +265.85%
Enliven Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $41 → $45
Current: $42.30
Upside: +6.38%
Wave Life Sciences
Mar 25, 2026
Maintains: Outperform
Price Target: $22 → $27
Current: $6.79
Upside: +297.64%
Cytokinetics
Mar 18, 2026
Maintains: Outperform
Price Target: $84 → $100
Current: $74.81
Upside: +33.67%
Maze Therapeutics
Mar 10, 2026
Initiates: Outperform
Price Target: $97
Current: $25.78
Upside: +276.26%
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $99.13
Upside: +22.06%
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $30.82
Upside: +29.79%
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $199.36
Upside: -15.23%
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $336.29
Upside: -16.74%
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $134.94
Upside: -13.29%
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $54.03
Upside: +201.68%
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $9.81
Upside: +83.49%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $52.83
Upside: +87.39%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.71
Upside: +1,128.07%